PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.84
-0.02 (-0.70%)
At close: 4:00PM EST

2.84 0.00 (0.00%)
After hours: 4:00PM EST

Stock chart is not supported by your current browser
Previous Close2.86
Open2.85
Bid2.85 x 800
Ask2.86 x 3200
Day's Range2.83 - 2.95
52 Week Range2.25 - 3.16
Volume1,534,844
Avg. Volume1,358,698
Market Cap414.572M
Beta (3Y Monthly)0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.45
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-02
1y Target Est3.00
Trade prices are not sourced from all markets
  • PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up
    Zacks4 days ago

    PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up

    PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.

  • ACCESSWIRE5 days ago

    3 Health Care Stocks Rallying After US Midterms

    / Healthcare stocks are rallying after Tuesday's US midterm elections. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data. Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of PDLI earnings conference call or presentation 6-Nov-18 9:30pm GMT

    Q3 2018 PDL BioPharma Inc Earnings Call

  • Associated Press6 days ago

    PDL BioPharma: 3Q Earnings Snapshot

    On a per-share basis, the Incline Village, Nevada-based company said it had profit of 18 cents. Earnings, adjusted for one-time gains and costs, were 9 cents per share. The biotechnology company posted ...

  • PDL BioPharma Reports Third Quarter 2018 Financial Results
    PR Newswire6 days ago

    PDL BioPharma Reports Third Quarter 2018 Financial Results

    Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three ...

  • PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
    PR Newswire12 days ago

    PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018

    INCLINE VILLAGE, Nev., Oct. 31, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018, after market close.  PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com. To access the live and subsequently archived webcast of the conference call, go to the Company's website and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

  • GlobeNewswire20 days ago

    Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PDL BioPharma Names Edward Imbrogno Vice President of Finance
    PR Newswirelast month

    PDL BioPharma Names Edward Imbrogno Vice President of Finance

    INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. ...

  • PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
    PR Newswire2 months ago

    PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • PDL BioPharma Announces New $100 Million Stock Repurchase Program
    PR Newswire2 months ago

    PDL BioPharma Announces New $100 Million Stock Repurchase Program

    INCLINE VILLAGE, Nev., Sept. 24, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission. "We believe this program is an appropriate means to create shareholder value given the current discrepancy between our share price and our book value," said John McLaughlin, Chief Executive Officer of PDL. The timing of purchases and the number of shares repurchased under the new program by PDL will depend on a variety of factors including price, trading volume, corporate and regulatory requirements and market conditions.  Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when PDL might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions.

  • Is PDL BioPharma (PDLI) a Great Stock for Value Investors?
    Zacks2 months ago

    Is PDL BioPharma (PDLI) a Great Stock for Value Investors?

    Is PDL BioPharma (PDLI) a great pick from the value investor's perspective right now? Read on to know more.

  • The 7 Best Biotech Stocks for Investors Who Hate Risk
    Kiplinger2 months ago

    The 7 Best Biotech Stocks for Investors Who Hate Risk

    Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)

  • PR Newswire2 months ago

    SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma

    Expresses Serious Concerns Regarding PDL's Misguided Acquisition Strategy, Which Has Destroyed Shareholder Value Believes the PDL Board Must Pursue Alternative Capital Allocation Strategies, Including ...

  • Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report?
    Zacks2 months ago

    Why Is PDL BioPharma (PDLI) Up 2.5% Since Last Earnings Report?

    PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • 3 Top Stocks Under $10
    Motley Fool2 months ago

    3 Top Stocks Under $10

    These low-priced stocks could generate high returns.

  • PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    PR Newswire2 months ago

    PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Parker Drilling, CoreLogic, Steven Madden, Diebold Nixdorf, Nevro, and PDL BioPharma — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Parker ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PDLI earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 PDL BioPharma Inc Earnings Call

  • PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
    Zacks3 months ago

    PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

    PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

  • Associated Press3 months ago

    PDL BioPharma: 2Q Earnings Snapshot

    The Incline Village, Nevada-based company said it had a loss of 76 cents per share. Earnings, adjusted for one-time gains and costs, were 10 cents per share. The biotechnology company posted revenue of ...

  • PDL BioPharma Reports Second Quarter 2018 Financial Results
    PR Newswire3 months ago

    PDL BioPharma Reports Second Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , Aug. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, ...

  • ACCESSWIRE3 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
    PR Newswire3 months ago

    PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

    INCLINE VILLAGE, Nev. , Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") ...

  • PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018
    PR Newswire3 months ago

    PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018

    INCLINE VILLAGE, Nev. , Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial ...

  • ACCESSWIRE4 months ago

    Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on PIRS sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com assesses Pacific Biosciences of California Inc. (NASDAQ: PACB), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), PDL BioPharma Inc. (NASDAQ: PDLI), and Pieris Pharmaceuticals Inc. (NASDAQ: PIRS).